Cabozantinib (a small molecule inhibitor of c-MET and VEGFR among other RTKs) was compared to selective anti-VEGFR inhibition in models of NB, and while anti-VEGFR therapy alone led to increased metastasis, cabozantinib decreased metastatic spread to visceral organs (though not to bones). This evidence concerns the gene MET and neuroblastoma.